Colleen, Zirou: Take 38 first imitation 18 billion market changes!

Pharmaceutical network August 17th, jiangxi Shanxiang Pharmaceuticals toluene sulfonate sorabeni tablets were approved for the domestic first imitation.
meters in-network data show that so far in 2020, 38 first imitation approved for listing, the original research products in 2019 China's public medical institutions terminal total sales of more than 18 billion; Subsidiary) led by 5 first imitations, Burglinger Ingeham, AstraZenemont has 5 varieties, 3 varieties were born first imitation, 14 heavy imitations are expected to be approved by the end of 2020, from Zhengda Tianqing, Hengrui, Yangzijiang and other enterprises.
Table 1: The first imitation rice network data approved for listing so far in 2020 show that so far in 2020, 38 first imitation (including dosage form first imitation) have been approved for listing, the original research products in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal sales of more than 18 billion yuan.
From the registration classification, 31 of the 38 first imitations submitted for listing in the new registration classification, approved after listing as through consistency evaluation, from the field of treatment, digestive and metabolic drugs, reproductive genitourinary system and sex hormone drugs, nervous system drugs accounted for "half of the mountain."
Zhengda sunny big winner, BI, AZ and other impact table 2: approved the first imitation of 2 and above enterprises 38 first imitation involving 29 pharmaceutical companies, Zhengda Qing, Howson, Dongsian medicine, Colleen, Jiangxi Shanxiang Pharmaceuticals 5 pharmaceutical companies were approved the first imitation of 2 and above.
Zhengda Tianqing (including subsidiaries) led with 5 first imitations, DPP-4 inhibitor siglitin, anti-HIV drug enqutabinofovir, new oral anticoagulant dabiga group esters in 20 Global sales in 19 years exceeded US$3.5 billion, US$2.8 billion and US$1.5 billion, respectively, and inhalation of Budinide suspension was the best-selling respiratory drug in China's public medical terminals in 2019, with sales of more than 7 billion yuan.
s three leading generics were followed by the schizophrenic drug Palifetone and SGLT-2 inhibitor Engele, which each had net global sales of more than $3 billion in 2019.
Sunshine Pharmaceuticals, Koren, Jiangxi Shanxiang Pharmaceuticals have 2 first imitation approved.
Essomera magnesium (Jiangxi Shanxiang took the first copy of the intestinal solution tablets, Dongsan medicine took the first intestinal dissolved capsule), Sorafini (Jiangxi Shanxiang took the first imitation) in 2019 In China's public medical institutions terminal sales of more than 1 billion yuan;
Figure: The number of varieties involved in 2 and above of the original research enterprises from the original research enterprises have been approved for import, 2020 to date, BurgerIngham 5 varieties have the first imitation approved, Afatiny, Liglietin, Dabiga group esters in 2019 China's public medical institutions terminal sales are more than 200 million yuan, AstraZeneira 3 varieties have the first imitation approved, inhalation of sulphuric acid Tebutalin solution, inhalation of Budinide mixed suspension, Essomerazole magnesium intestinal tablets in 2019 China's public medical institutions terminal sales of more than 1 billion yuan.
fu, Hai Zheng... 4 major products to make up for the domestic blank market Table 3: the first approved products in China injection of sodium severin is a neutral granulocyte elastinase inhibitor, with a clear inhibition of lung damage, improve lung function effect, is the first approved for the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) drugs, from CDE to the approval of the market, took less than a month.
Cyclosporine Eye Drops, developed by Aerjian, is the world's first drug for the cause of dry eye disease, with global sales of $1,189 million in 2019, and the original product has yet to enter the domestic market.
shenyang Xingqi eye medicine cyclosporine eye drops (II.) is the first in China to treat dry eye disease as an adaptation of cyclosporine-type eye drops.
a broad-spectrum antiviral drug developed by Toyama Chemical Industry Co., Ltd. of Japan, the core patent expired in August 2019, and the original product has not yet entered the domestic market.
Pharmaceuticals' products were conditionally approved for production in February 2020 for the treatment of new or re-epidemic influenza in adults, in addition to the new infection of coronavirus pneumonia approved clinically.
is sunny, Hengrui ... 14 first imitation approved in table 3: is expected to be approved for listing by the end of 2020, the heavy first imitation of rice network data show that 14 heavy imitation drugs are expected to be approved for listing by the end of 2020, involving Zheng Datianqing, Hengrui, Dongsian medicine, Yangzijiang, Qilu and other enterprises, a number of original research products in 2019 global sales of more than 1 billion U.S. dollars.
Azishatan is an AngII receptor antagonist developed by Takeda, with global sales of 76.7 billion yen in 2019, the original research product has not yet been approved in China, Hengrui in August 2017 the first to copy category 3 Tovaputan is an oral selective arginine pressurized V2 receptor antagonist developed by Otsuka Pharmaceuticals, which entered the domestic market in 2011 and was the first to be produced in April 2019 under imitation.
Lunvatini is a multi-target kinase inhibitor developed by Weiss, the original research products were approved for import in September 2018, 2019 sales in China has exceeded 1 billion yuan, is the first in June 2019 to Imitation of Category 4 newspapers; 15 snatched propofol-to-nofowe as an upgraded version of the initial treatment drug for foreign hepatitis B, steroxane dipire, developed by Gilead, with global sales of $488 million in 2019 Sunny was the first to be produced in October 2018 in a generic Category 3, and Ivemos is the fda-approved first repamycin (mTOR) inhibitor, with global sales of $2,024 million in 2019, with positive day in 2018 November, reported for domestic exclusive; Pomadamine is a new base developed is an immunomodant, 2019 global sales of $2.55 billion, the original research has not yet been approved for import, is the first report in August 2018.
Shakuba Qushatan is a heart failure drug developed by Novarro, with global sales of US$1.726 billion in 2019, entered the domestic market in 2017, was negotiated into the national health insurance in 2019, the composition patent was invalidated in 2018, and Shanghai Xuantai Haimen first reported production in November 2018.
Percilli is the world's first selective cell cycle protein-dependent kinase (CDK) 4/6 inhibitor, with global sales of $4,961 million in 2019, original research products approved for import in June 2018, and Qilu in November 2018 the first to be produced in imitation category 4.
Sodium saccharin is the world's first specific binding neuromuscular blocking antagonism drug developed by Mercerton/Oganon, with global sales of US$1,131 million in 2019, entered the domestic market in April 2017, and Colum was the first to report in November 2018 under the generic category 4.
: MED2.0 China Drug Review Database Note: Data statistics as of August 13, if there are omissions, welcome to point the right!